No Data
No Data
Eupraxia Pharmaceuticals Up 5.5% In US Premarket As Says DiffuSphere Technology Demonstrates Targeted Drug Release
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release While Minimizing Systemic Exposure for a Period of More Than Six Months
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Express News | Eupraxia Pharmaceuticals Inc : Raymond James Cuts Target Price to $12 From $16.50
MT Newswires Stocks To Watch: Eupraxia Pharmaceuticals and I-80 Gold. Also Conifex, Crown; Dream Unlimited; DCM; NGEx; Peyto; Primaris REIT; VIQ Solutions